TS03 Inc Trust Units TSTIF

Further Thoughts...

[echo2]

I will only address a few issues in my medical area raised by these manipulating short players in their published garbage:

 

1. TSO3 is completely outclassing the competition. These goofs argue that Steris’s VPro and Sterrad/JNJ’s NX versions are equivalent to the VP4, or at least they have nicer buttons. Come on? The VP4 doesn’t have as many cycles because it doesn’t need them: one cycle in one chamber that fits far more instruments than the competition! The user does not need to push a combination of buttons to fit the particular instruments because one button is all that is needed. And, note, the VP4 cycle time is 46 minutes because it actually runs the H2O2 and Ozone through twice, and thus the end user is completely assured that the load is sterile. Every load. Sterrad did update their machine last year? by trying to make it easier to use to determine which cycles to use with a software upgrade, but their technology is far older than TSO3’s. And, they cannot sterilize the complex long multichannel scopes (complex colonoscopes, duodenoscopes, etc.) that the VP4 can sterilize. They have not even applied for the FDA extended claims that TSO3 has obtained and applied for because their older outdated technology does not sterilize these scopes, and never will. Period. And, with time and their new testing and validation lab in Myrtle Beach, the compatibility matrix for the VP4 is growing constantly and relevant to the users, including scopes, such as the Olympus Q180V, that are predominant in the operating room and GI suite. It has been found that the VP4 can do 8-9+ cycles per day, more effectively and efficiently… and saving money to users in the process than the so-called competition. If Sterrad and Steris are having to try to undercut Getinge and TSO3 in terms of price in order to consummate a replacement sale, does that alone not indicate that they are afraid of this revolutionary technology and they can’t compete on product?? Give us a break! TSO3 has better technology, hands down, and the patents for all of it. Period. 
2. If you want to see what the VP4 and TSO3 can do, and compare it to the competition (if you can call that competition!) just check out the new presentation from a few weeks ago on the website (this is an absolute must see for everyone!!!) https://www.tso3.com/media/application/media/Corporate%20Presentation_August%202017.pdf
3. The rag notes that the FDA does not include the VP4 as a recommended solution to the duodenoscope contamination problem. Might it be worth understanding (dah?) that the FDA recommendations were made over 2 years ago in 2015, before FDA extended claims unique to the VP4 for long complex multichannel flexible scopes? (Dah?) The FDA has not yet (DAH?) approved the VP4 for sterilizing duodenoscopes at this time. This approval has only been recognized in Canada and Europe. TSO3 submitted the data for this recently, and when this claim is given in coming months, it will be very very positive for TSO3, and their shareholders, of course!
4. They then go on to ‘discuss’ market products for addressing the ‘superbug’ problem, including, and don’t laugh, high temperature steam, dry heat, filtration, ionizing radiation. Really? Do they have no understanding of what and why low temperature sterilization exists? Some instruments cannot be heat sterilized, and you can’t put a duodenoscope through a filter and sterilizing its surface with radiation is beyond useless. The low temperature sterilization sector is THE growing sector in the sterilization field, and the GI space is a greenfield for TSO3's unique technology because it is the only technology that works in this space! Low temperature sterilization is being used to replace steam! And, the ETO sterilizer (that would be ethylene oxide, for Mr. Axler, is that this genius’s name?) is outdated, inefficient, incredibly toxic, and expensive...
5. The FDA has just two weeks ago, and much sooner than anticipated, mandated that all new or updated 510k premarket approval applications for a host of instruments, including the relevant scopes, include data for sterilization of these scopes or instruments. This means the FDA recognized sterilization of these scopes and instruments is essential from now on. Once the VP4 has been approved for existing duodenoscopes the FDA will be able to mandate sterilization of older in-use scopes as well. The VP4 is the only low temperature sterilizer that can make sterilization claims for these scopes, and the old technologies never will be able to say this. They don’t work. The VP4 does! TSO3’s use of Ozone on top of H2O2 allows it to sterilize deeper and more effectively in scopes, and the amount of ozone used in the new VP4 is reduced to a level that is effective in sterilization but not as harsh on the lubricants and seals of some scopes. TSO3 at Myrtle Beach is also working with scope manufacturers and servicing companies to develop and utilize lubricants and materials that are even more compatible with H2O2 and ozone to ensure that scopes last even much longer without servicing.
6. As noted previously, Getinge acquired Stericool, a relatively insignificant Turkish manufacturer of a knockoff H2O2 sterilizer that is not patented and has no approval for use in N. America), for $6.95 M US. This company cannot in any way be compared to TSO3, either in the quality of the product, its applications, or its future.
7. These idiots site FDA information when the VP4 obtained approval 3 years ago as being ‘substantially equivalent’ to the inferior competition, and they even present an outdated table to make this seem relevant. A lot has happened in the three years since in terms of FDA recognition of the VP4’s superiority and more recognition will come with more unique extended claims for the VP4 regarding duodenoscopes: the VP4 is the only low temperature sterilizer approved for long up to 4 channel complex flexible scopes!! Again. Period. These guys fail to note that the FDA issued a unique identifier for the TSO3 technology, recognizing it as the only dual sterilant low temperature sterilizer available. Their reference to ‘industry observers’ not recognizing that ozone is a key differentiator of the VP4 merely further demonstrates the profound ignorance of these ‘observers’ and this short seller. Sterrad uses ‘plasma’ to the same end that TSO3 uses Ozone? What are they talking about? They have no idea whatsoever of what they are talking about! Ozone on top of the vaporized H2O2 is a sterilant and aids with deeper and more effective sterilization that the VPro and Sterrad units simply cannot match!
8. They also refer to a blog by chemDAQ. But, here they border on frank and misleading fraud by stating that chemDAQ stated that “ozone is unlikely to have any effect” on sterilization. chemDAQ says nothing of the kind on their blog. In fact they state, “the Sterrad’s plasma may not make a huge difference to sterilization efficiency, it has had a huge impact in the marketing department. We can expect similar benefits for TSO3 from their dual hydrogen peroxide/ozone sterilizer.” This is not to say the use of ozone does not improve the sterilizing capabilities of the VP4 or the upcoming smaller 80L unit by TSO3. It states this dual sterilant is a positive and makes no comment at all on the science or the efficacy of the dual sterilant or on ozone. On the other hand, the FDA did recognize the importance of the dual sterilant when they gave the VP4 a unique identifier with its approval.
9. Apart from this manipulative shorter’s jaded, ridiculous, grossly misinformed, and biased opinion, the average analyst target for TSO3 is $4.95

 

However, many unaware investors were fleeced today by these manipulators and their superficially in-depth analysis, that on closer inspection is absolute fear-mongering drivel and garbage. The shorts, including these slimes at Spruce, their friends, and family, etc., made a ton of money today. Do not sell to them. Buy. I did. Rumble did.

 

The company may not believe addressing this drivel is worthy of their time, as they have real business to transact, real science to apply, real people’s health care to improve… But, I hope my analysis opens the eyes of some of you. Don’t jump! Buy!

 

 

More to come…